Perimeter Medical Imaging AI: A Breakthrough in Cancer Surgery

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) has just reported its fourth quarter and full year 2024 financial results, and the numbers are nothing short of spectacular. The company, which specializes in ultra-high-resolution, real-time, advanced imaging tools for cancer surgery, saw a 303% increase in Q4-2024 revenues compared to Q4-2023. This surge is a clear indicator of the commercial traction and market acceptance of their S-Series OCT system, which provides real-time, cross-sectional visualization of excised tissues at the cellular level.

The 303% increase in Q4-2024 revenues is a testament to the company's success in placing more systems and increasing utilization. In 2024, Perimeter achieved nine (9) new S-Series OCT system placements, compared to only three (3) in 2023. This nearly threefold increase in system placements directly correlates with the surge in revenue, as more hospitals and surgical centers are adopting the technology.



But the story doesn't end there. Perimeter's next-generation B-Series OCT system, which combines proprietary AI technology with OCT, is currently under clinical development and has shown promising results. In November 2024, Perimeter reported topline results from the pivotal study designed to support its Premarket Approval (PMA) application to the FDA for B-Series OCT with ImgAssist AI 2.0. The pivotal trial met its primary endpoint, achieving a statistically significant (p-value = 0.0050) reduction in patients with residual cancer during surgery. These results demonstrated super-superiority of the Perimeter B-Series' ability to aid surgeons in achieving clear surgical margins during surgery, potentially lowering the need for reoperation.

The implications for future revenue growth are promising. The successful commercial traction and market acceptance of the S-Series OCT system suggest that Perimeter Medical Imaging AI is well-positioned to continue expanding its customer base and increasing revenue. The company's strategic focus on advancing its next-generation B-Series OCT system, which combines proprietary AI technology with OCT, further enhances its growth potential. As the B-Series system progresses through clinical trials and regulatory approvals, it is expected to contribute significantly to future revenue growth, potentially lowering the need for reoperation and improving surgical outcomes.



The 110% increase in full-year 2024 revenues compared to 2023 is driven by the successful commercialization of the S-Series OCT system, positive results from the pivotal clinical trial of the B-Series OCT, strategic partnerships, and geographic expansions. These factors not only contribute to short-term revenue growth but also position Perimeter Medical Imaging AI for sustained long-term growth in the medical imaging sector through continued innovation, market penetration, and regulatory approvals.

In summary, Perimeter Medical Imaging AI's fourth quarter and full year 2024 financial results are a clear indication of the company's success in the medical imaging sector. The company's innovative technology, strategic partnerships, and geographic expansions position it for sustained long-term growth. As the B-Series system progresses through clinical trials and regulatory approvals, it is expected to contribute significantly to future revenue growth, potentially lowering the need for reoperation and improving surgical outcomes.